Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes

Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00655044

Acronym

PREDICTIVE™

Enrollment

3637

Registered

2008-04-09

Start date

2007-05-31

Completion date

2008-01-31

Last updated

2016-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.

Interventions

DRUGinsulin detemir

Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.

Study design

Observational model

CASE_CONTROL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Type 1 diabetes * Type 2 diabetes * Candidates of use of a basal insulin as part of their diabetes regimen

Exclusion criteria

* Unwilling to adhere to therapy or follow up * Pregnancy

Design outcomes

Primary

Measure	Time frame
HbA1C	after 12 weeks

Secondary

Measure	Time frame
Safety	during treatment

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026